Equities

Progyny Inc

PGNY:NSQ

Progyny Inc

Actions
Health CareHealth Care Providers
  • Price (USD)16.47
  • Today's Change-7.97 / -32.61%
  • Shares traded14.47m
  • 1 Year change-52.59%
  • Beta1.4388
Data delayed at least 15 minutes, as of Sep 19 2024 19:48 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy2
Outperform4
Hold5
Sell0
Strong Sell0

Share price forecast in USD

The 7 analysts offering 12 month price targets for Progyny Inc have a median target of 26.00, with a high estimate of 31.00 and a low estimate of 21.00. The median estimate represents a 6.38% increase from the last price of 24.44.
High26.8%31.00
Med6.4%26.00
Low-14.1%21.00

Earnings history & estimates in USD

On Aug 06, 2024, Progyny Inc reported 2nd quarter 2024 earnings of 0.17 per share. This result was in line with the consensus of the 10 analysts following the company and exceeded last year's 2nd quarter results by 13.33%.
The next earnings announcement is expected on Nov 05, 2024.
Average growth rate+4.67%
Progyny Inc reported annual 2023 earnings of 0.62 per share on Feb 27, 2024.
Average growth rate+166.82%
More ▼

Revenue history & estimates in USD

Progyny, Inc. had 2nd quarter 2024 revenues of 304.09m. This missed the 305.42m consensus estimate of the 9 analysts following the company. This was 17.68% above the prior year's 2nd quarter results.
Average growth rate+2.25%
Progyny, Inc. had revenues for the full year 2023 of 1.09bn. This was 38.34% above the prior year's results.
Average growth rate+47.71%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.